Intravitreal injection of erythropoietin protects both retinal vascular and neuronal cells in early diabetes
- PMID: 18235022
- DOI: 10.1167/iovs.07-0721
Intravitreal injection of erythropoietin protects both retinal vascular and neuronal cells in early diabetes
Abstract
Purpose: To explore and evaluate the protective effect of erythropoietin (EPO) on retinal cells of chemically induced diabetic rats after EPO was injected intravitreally at the onset of diabetes.
Methods: Diabetes was induced in Sprague-Dawley rats by intraperitoneal injection of streptozotocin (STZ). At the onset of diabetes, a single intravitreal injection of EPO (0.05-200 ng/eye) was performed. In the following 6 weeks, the blood retinal barrier (BRB) was evaluated by Evans blue permeation (EBP). Retinal cell death in different layers was determined by terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) staining. The retinal thickness and cell counts were examined at the light microscopic level. Electron microscopy (EM) was used to scrutinize retinal vascular and neuronal injury. Neurosensory retinas of normal and diabetic rats were used as the sources of reverse transcription-polymerase chain reaction (RT-PCR) and Western blot for the detection of EPO, EPO receptor (EpoR), and products of the extracellular signal-regulated kinase (ERK) and the signal transducers and activators of transcription 5 (STAT5) pathways. The distribution of EpoR in retinal layers was demonstrated by immunohistochemistry (IHC).
Results: In the diabetic rats, BRB breakdown was detected soon after the onset of diabetes, peaked at 2 weeks, and reached a plateau at 2 to 4 weeks. The number of TUNEL-positive cells increased in the neurosensory retina, especially, the outer nuclear layer (ONL) at 1 week after diabetes onset and reached a peak at 4 to 6 weeks. The retinal thickness and the number of cells in the ONL were reduced significantly. EM observations demonstrated vascular and photoreceptor cell death starting soon after the onset of diabetes. All these changes were largely prevented by EPO treatment. Upregulation of EpoR in the neurosensory retina was detected at both the transcriptional and protein levels 4 to 8 weeks after the onset of diabetes, whereas, the endogenous EPO levels of neurosensory retinas were essentially unchanged during the same period observed. In EPO-treated diabetic groups, EpoR expression remained at upregulated levels. Within 2 weeks of the onset of diabetes, activation of the ERK but not the STAT5 pathway was detected in the diabetic retina treated with EPO.
Conclusions: These data demonstrate that apoptosis is an major contributor to neuronal cell death in the early course of diabetic retinopathy (DR). The upregulation of EpoR may be a compensatory response of retinal cells and tissue to diabetic stresses. The EPO/EpoR system as a maintenance-survival mechanism of retinal neurons responds to the insults of early diabetes other than ischemia. The protective function of EPO/EpoR at the least acts through the EpoR-mediated ERK pathway. Exogenous EPO administration by intravitreal injection in early diabetes may prevent retinal cell death and protect the BRB function. Therefore, this is a novel approach for treatment of early DR.
Similar articles
-
Erythropoietin protects outer blood-retinal barrier in experimental diabetic retinopathy by up-regulating ZO-1 and occludin.Clin Exp Ophthalmol. 2019 Dec;47(9):1182-1197. doi: 10.1111/ceo.13619. Epub 2019 Sep 15. Clin Exp Ophthalmol. 2019. PMID: 31483932
-
Intravitreal injection of erythropoietin protects against retinal vascular regression at the early stage of diabetic retinopathy in streptozotocin-induced diabetic rats.Exp Eye Res. 2013 Jan;106:64-73. doi: 10.1016/j.exer.2012.11.001. Epub 2012 Nov 21. Exp Eye Res. 2013. PMID: 23178551
-
Erythropoietin protects the inner blood-retinal barrier by inhibiting microglia phagocytosis via Src/Akt/cofilin signalling in experimental diabetic retinopathy.Diabetologia. 2021 Jan;64(1):211-225. doi: 10.1007/s00125-020-05299-x. Epub 2020 Oct 26. Diabetologia. 2021. PMID: 33104828
-
Erythropoietin receptor response circuits.Curr Opin Hematol. 2010 May;17(3):169-76. doi: 10.1097/MOH.0b013e328338008b. Curr Opin Hematol. 2010. PMID: 20173635 Free PMC article. Review.
-
Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system.Neurotherapeutics. 2009 Jan;6(1):108-27. doi: 10.1016/j.nurt.2008.10.041. Neurotherapeutics. 2009. PMID: 19110203 Free PMC article. Review.
Cited by
-
Hyperoside Ameliorates Diabetic Retinopathy via Anti-Oxidation, Inhibiting Cell Damage and Apoptosis Induced by High Glucose.Front Pharmacol. 2020 May 29;11:797. doi: 10.3389/fphar.2020.00797. eCollection 2020. Front Pharmacol. 2020. PMID: 32547397 Free PMC article.
-
Novel targets against retinal angiogenesis in diabetic retinopathy.Curr Diab Rep. 2012 Aug;12(4):355-63. doi: 10.1007/s11892-012-0289-0. Curr Diab Rep. 2012. PMID: 22638940 Review.
-
MicroRNA-150 (miR-150) and Diabetic Retinopathy: Is miR-150 Only a Biomarker or Does It Contribute to Disease Progression?Int J Mol Sci. 2022 Oct 11;23(20):12099. doi: 10.3390/ijms232012099. Int J Mol Sci. 2022. PMID: 36292956 Free PMC article. Review.
-
Using the past to inform the future: anti-VEGF therapy as a road map to develop novel therapies for diabetic retinopathy.Diabetes. 2013 Jun;62(6):1808-15. doi: 10.2337/db12-1744. Diabetes. 2013. PMID: 23704522 Free PMC article.
-
Prediction of diabetic retinopathy: role of oxidative stress and relevance of apoptotic biomarkers.EPMA J. 2010 Mar;1(1):56-72. doi: 10.1007/s13167-010-0002-9. Epub 2010 Mar 23. EPMA J. 2010. PMID: 23199041 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous